Experimental drug that builds muscle

[Nelson Vergel]

Eli Lilly has licensed rights to an experimental drug that builds muscle to Canada's Transition Therapeutics.
The big pharma company pockets just $1m upfront from the deal, although Transition could pay up to $100m in milestones if the small-molecule drug - called TT701 - eventually reaches the market.

TT701 is a selective androgen receptor modulator (SARM) that has been shown to increase lean body mass and muscle strength in male subjects, whilst also reducing fat levels in the body.

Despite its effect on testosterone levels there was no accompanying increase in prostate specific antigen (PSA) levels. PSA levels are known to rise with testosterone replacement therapy (TRT) and there have been concerns TRT could activate or exacerbate prostate hyperplasia or prostate cancer.

http://www.pmlive.com/pharma_news/t...muscle-boosting_drug_734054?SQ_DESIGN_NAME=2&

It is not clear immediately what indications Transition will pursue for TT701. In the past, Lilly has tested SARMs in tandem with its Cialis (tadalafil) drug for erectile dysfunction (ED), while in recent years there has been growing interest in TRT to help men avoid age-related consequences of declining testosterone levels.

 

[PAUL-E]

Transition’s TT701, a once-daily oral selective androgen receptor modulator for patients with androgen deficiency. In a 12-week study of 350 male subjects, TT701 showed significantly decreased fat mass and increased lean body mass and muscle strength without significantly changing prostate specific antigen levels.
.
TT701 is in phase 2 clinical trials
http://www.genengnews.com/gen-news-...-to-acquire-transition-therapeutics/81252896/

 

[Re-Ride]

Here's to a rip roaring 4ht of July for all men. Let's hope you're nice not naughty then Santa brings you TT701 instead of vials and 18 ga pins.

 

[ERO]

Wow - this drug almost looks too good to be true. increased lean mass & strength plus fat reduction. Perfect if it works as advertised.

 

[Jinzang]

Here is the page describing TT401 from Transition Therapeutics. It's being marketed as a treatment for Type 2 Diabetes.

The fastest growing segment of the diabetes market is the class of GLP-1 single-agonist therapies. TT401, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity, is a dual agonist of the GLP-1 (Glucagon-Like Peptide-1) and glucagon receptors. These receptors play an integral role in regulating appetite, food intake, satiety and energy utilization in the body. Stimulating both these receptors, TT401 has the potential to regulate blood glucose levels with important additional outcomes, such as weight loss.

Doesn't sound like it binds to androgen receptors, so don't see how it's a SARM.

http://www.transitiontherapeutics.com/technology/tt401.php

 

[MikeXL]

you are looking at a different compound. Nelson was talking about TT1701 not tt401